Skip to main content

2 Result(s)

within Bryan K. Kee Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. Article

    Open Access

    A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

    Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical successes, but drug resistance often develops due to aberrant or co...

    Sarina A. Piha-Paul, Chieh Tseng, Hai T. Tran… in Cancer Chemotherapy and Pharmacology (2023)

    Download PDF (647 KB) View Article

  2. No Access

    Article

    Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver

    Background Liver metastases are associated with a poor prognosis. We investigated the use of hepatic arterial infusion (HAI) of irinotecan combination therapy in patients with liver metas...

    Rabih Said, Razelle Kurzrock, Aung Naing, David S. Hong… in Investigational New Drugs (2015)